Skip to main content
. 2006 Apr;65(4):557–559. doi: 10.1136/ard.2005.042937

graphic file with name ar42937.f1.jpg

Figure 1 Case 1: (A) sequential eosinophil and CD19 counts and (B) Birmingham Vasculitis Activity Score (BVAS) and prednisolone dose after rituximab administration. Case 2: (C) sequential eosinophil and CD19 counts and (D) BVAS and prednisolone dose after rituximab administration.